NCT02715479View on ClinicalTrials.gov

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

Dolutegravir

Dolutegravir

DRUG

BMS955176

BMS955176

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY